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A 59-year-old woman with hypertrophic cardiomyopathy
of　 8　 years　 duration,　 who　 had　 been　 taking β-blocker,　 was
admitted to our hospital for exertional dyspnea and previ-
ous syncope. Cardiac catheterization showed a prominent 
left-ventricular outflow tract (LVOT) pressure gradient, 
and hypertrophic obstructive cardiomyopathy (HOCM) was 
diagnosed. To reduce LVOT obstruction, we implanted a 
single-lead VDD-mode pacemaker. Cardiac catheterization 
after the implantation revealed a remarkable decrease in 
the LVOT pressure gradient with short atrioventricular 
delay, 80 msec, and her symptoms disappeared. A single-
lead VDD pacemaker is also a useful treatment for an 
HOCM patient due to the relative ease with which it can be 
implanted.
valve replacement'-'), or atrioventricular sequential 
pacing10"5. But surgery frequently fails to reduce 
LVOT obstruction and leads to a 2-11 % possibility of 
early mortality". Dual-chamber pacing has been shown 
to induce the reduction of the LVOT pressure gradient 
and to lead to improvement in symptoms of 
hypertrophic obstructive cardiomyopathy (HOCM). 
Recently single-lead VDD pacing",") has been used 
widely to patients with advanced atrioventricular 
block. We report a decrease in the LVOT pressure 
gradient by single-lead VDD pacing in an HOCM pa-
tient.
Case Report
Key words: single-lead VDD pacing, hypertrophic obstructive 
         cardiomyopathy (HOCM), left-ventricular outflow 
          tract obstruction
Introduction
 The degree of obstruction of the left ventricular out-
flow tract (LVOT) is an important determining factor 
in the clinical course of patients with hypertrophic 
cardiomyopathy(HCM). To relieve the LVOT obstruc-
tion, the initial therapeutic approach is pharmacothe-
rapy such as 1 -blocker and verapamil1-4'. However, 
many patients develop a resistance to such therapies. 
The next approach is either surgery involving 
left ventricular septal myectomy or mitral
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 On 25 December 1998, a 59-year-old woman was ad-
mitted to our hospital for further examinations due to 
exertional dyspnea, chest pain and a history of syn-
cope. She had been diagnosed as having HCM in an-
other hospital about 8 years before and had received 
medicinal treatment, (9 -blocker, and antiplatelet ther-
apy. On admission, electrocardiography (ECG) showed 
T inversion in leads I, II, aVL, aVF, and V4-V6; ST ele-
vation in leads V 1 and V2; and high voltage (S V 1 + 
RV5 = 8.59 mV). Cardiomegaly (cardiothoracic ratio: 
63.7 %) was observed by thoracic radiography (Fig. 1, 
left). Concentric left-ventricular hypertrophy with 17-
to 19-mm wall thickness and LVOT narrowing were 
shown by echocardiography (Fig. 2). Hematology and 
biochemistry results showed iron deficiency anemia 
and high LDH (679 IU/1). We performed cardiac 
catheterization on the day of admission. Pressure 
study revealed a left ventricule (LV) -aorta (Ao) pres-
sure gradient of 112 mmHg, and left ventriculography 
of right-anterior, oblique view showed a spade-like 
shape, which was compatible with HCM, during sys-
tolic phase. Coronary angiography showed no signifi-
cant stenosis.
Fig. 1. Chest X-ray. Left, before implantation of pacemaker (CTR: 63.7%); right, after single-lead VDD pacemaker implan-
tation (CTR: 61.0%). CTR: cardiothoracic ratio
Fig. 2. Echocardiography. A, two-dimensional apical view during systolic phase; B, short axis view of LV at end-diastolic 
phase; C, systolic anterior movement (SAM) of mitral valve on M-mode. LV: left ventricle; LVOT: left ventricular out flow 
tract; Ao: Aorta; LA: left atrium.
Fig. 3 Pressure curve from left ventricle to aorta before (left) and after VDD pacing (right). LV: left ventricle; LVOT: left ven-
tricular out flow tract; Ao: Aorta; PG: pressure gradient.
 Holter ECG recording showed occasional premature 
atrial contractions, including atrial tachycardia, but no 
long pause and no ventricular tachycardia that caused 
syncope, and no significant ST-T change. 
 We thought her symptoms were caused by HOCM 
and the pharmacotherapy was not enough to decrease 
the high degree of pressure gradient in LV. Therefore 
it was necessary for her to undergo further treatment, 
either atrioventricular (AV) sequential pacing or sur-
gery. She hoped the treatment of the pacing, and we 
implanted her a single-lead VDD-mode pacemaker 
(Unity 292-07, Intermedics) on 13 January (Fig. 1, 
right). Before this procedure, we did not identify the 
acute useful effects of this treatment with temporary 
pacing. One reason was that she hoped early treat-
ment and short hospitalization. Another reason was 
that Fananaparzir et al 12' reported the acute study is 
not always necessary because chronic effects are more 
beneficial than acute effects. One week after the im-
plantation, the second cardiac catheterization was per-
formed. We measured the LVOT pressure gradient 
(Fig. 3) while changing the AV delay intervals (AV 
delay). As AV delay was shortened, the LV systolic 
pressure and the LVOT pressure gradient decreased 
(Table 1). There were, however, no remarkable 
changes under 80 msec AV delay, and so we pro-
grammed the AV delay at 80 msec. Cardiac output
Table 1. Changes of pressure in LV and Ao at various AV delay
AV delay LVSP AoSP LV-AoPG 
  250 250 152 98 
  120 218 171 47 
  100 210 174 36 
  80 202 163 39 
  70 204 160 44 
  60 198 163 35
LV: left-ventricle. Ao: Aorta. LVSP: left-ventricular systolic pressure, 
mmHg. AoSP: Aortic systolic pressure, mmHg. LV-AoPG: Pressure 
gradient between left-ventricle and aorta, mmHg.
was not measured with the thermo-dilution method, 
because the manipulation involved in such measure-
ments might displace the pacing lead from the 
endocardium. Echocardiography revealed no differ-
ences in LV function between before and after implan-
tation of the pacemaker. After the implantation of 
pacameker, her symptoms were not occurred during 
the hospitalization.
Discussion
 Dual-chamber pacing for patients with HOCM has 
been shown to be an effective treatment for reduction of
LVOT obstruction and improvement of symptoms ....... 
Jeanrenaud et al."' reported that decrease of the LVOT 
pressure gradient without decrease of arterial pressure 
and cardiac output was observed immediately after im-
plantation of a DDD pacemaker, and after 3 to 30 
months, the symptoms such as dyspnea, angina, and 
syncope, were also reduced. In another study that in-
cluded a 1.5 to 3 months follow-up, the nearly identi-
cal hemodynamic changes to those reported by 
Jeanrenaud et al. were apparent, even when DDD pac-
ing was discontinued 13'. A long term study (2.3 years) 
revealed that the LVOT pressure gradient and LV sys-
tolic pressure continued to decrease overtime, indicat-
ing an excellent prognosis"'. It has been considered 
that these beneficial effects of DDD pacing to HOCM 
patients were due to the right ventricular apical 
preexcitation, which occurred asynchronous ventricu-
lar contraction and consequently decreased LVOT 
pressure gradient. Furthermore, in the long term 
study, chronic DDD pacing was reported to reduce LV 
wall thickness, especially of the basal anterior and dis-
tal anterior septal segments. Jeanrenaud and 
Kappenberger15' also demonstrated by echocardiogra-
phy that DDD pacing reduces ventricular septal wall 
motion, which contributes to relieving LVOT obstruc-
tion. Regarding VDD pacing, Pak et al."' reported that 
pacing shifts the end-systolic pressure-volume relation 
to rightward and increases end-systolic volume in LV, 
which reduces intracavity pressure gradient and low-
ers total chamber workload in HCM. Short AV delay 
VDD pacing is apparently superior to DDD pacing be-
cause it does not influence mean arterial pressure and 
stroke volume of the LV in patients with poor left 
ventricular function who have undergone coronary by-
pass surgery"). Single-lead VDD pacing was established 
about 10 years ago, and its use has spread. It is easier 
to implant a VDD pacemaker than that a DDD pace-
maker because the VDD uses only one lead. 
Furthermore, a VDD pacemaker preserves the patients' 
own sinus beat better than a DDD pacemaker does. 
Therefore we chose VDD pacing for our patient. 
 The optimal AV delay is an important factor when 
using atrioventricular sequential pacing for HOCM pa-
tients. The pacing must always excite the right ven-
tricular apex before normal cardiac conduction and 
must induce atrial contraction with sufficient ventricu-
lar volume. Reports of the optimal AV delay have var-
ied: 75-125 msec13', 76 msec on average's', and 75 
msec18'. Jeanrenaud et al.'2' suggested that optimal AV 
delay should be programmed individually. We deter-
mined the most beneficial AV delay to reduce LVOT 
obstruction in our particular patient and programmed 
in the delay of 80 msec. At this delay, echocardiography
showed no remarkable change in her LV function be-
fore and after implantation of the pacemaker. 
 The implantation of a single-lead VDD pacemaker 
improved hemodynamics and symptoms in our patient. 
However, her intracavity pressure has remained high, 
about 200 mmHg, and further follow-up examination, 
therefore, will be required.
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